SDG3
2025 “Clinical Proteome Microarray Forum” Focuses on Innovative Applications of High-Throughput Protein Microarray Technology
The “Clinical Proteome Microarray Forum (臨床蛋白體晶片應用論壇)”, integrating expertise from Taiwan’s medical centers, universities, and biotechnology industries, was held on December 12, 2025, at the Fengbei Lecture Hall, 1st Floor, Biomedical Excellence Building, National Cheng Kung University (NCKU). Based in Taiwan, the forum is dedicated to promoting innovative applications of high-throughput protein microarray technology in the field of precision medicine, with the goal of becoming an international hub for technology and industry exchange.
This forum, held for the first time in 2025, was organized by the High-Throughput Protein Microarray Technology and Biomedical Industry Service Alliance, guided by the National Science and Technology Council (NSTC), and co-organized by students from NCKU’s course “Industrialization and Expansion of Innovative Technology Services”. The forum aims to build a world-class high-throughput protein microarray platform.
The platform developed by the High-Throughput Protein Microarray Technology and Biomedical Industry Service Alliance can cover thousands to tens of thousands of proteins, supporting large-scale, high-throughput protein interaction and immunoassays. It provides high-efficiency, high-resolution technical support for antibody screening, disease mechanism analysis, companion diagnostics, and precision medicine research and development.
The forum gathered experts from NCKU, China Medical University, Kaohsiung Chang Gung Memorial Hospital, and top Taiwanese universities, medical institutions, and biotech industries to explore breakthrough applications of high-throughput protein microarray technology in areas such as antibody-drug conjugate development, cancer immunotherapy, neuroinflammation mechanisms, autoimmune disease diagnostics, and rare disease treatment, aiming to accelerate the translation of innovative technologies from the laboratory to the clinic and market.
Five keynote lectures were arranged to showcase clinical translation breakthroughs of protein microarrays:
This forum, held for the first time in 2025, was organized by the High-Throughput Protein Microarray Technology and Biomedical Industry Service Alliance, guided by the National Science and Technology Council (NSTC), and co-organized by students from NCKU’s course “Industrialization and Expansion of Innovative Technology Services”. The forum aims to build a world-class high-throughput protein microarray platform.
The platform developed by the High-Throughput Protein Microarray Technology and Biomedical Industry Service Alliance can cover thousands to tens of thousands of proteins, supporting large-scale, high-throughput protein interaction and immunoassays. It provides high-efficiency, high-resolution technical support for antibody screening, disease mechanism analysis, companion diagnostics, and precision medicine research and development.
The forum gathered experts from NCKU, China Medical University, Kaohsiung Chang Gung Memorial Hospital, and top Taiwanese universities, medical institutions, and biotech industries to explore breakthrough applications of high-throughput protein microarray technology in areas such as antibody-drug conjugate development, cancer immunotherapy, neuroinflammation mechanisms, autoimmune disease diagnostics, and rare disease treatment, aiming to accelerate the translation of innovative technologies from the laboratory to the clinic and market.
Five keynote lectures were arranged to showcase clinical translation breakthroughs of protein microarrays:
- 1. Shih-Hsien Chuang (莊士賢), CEO of HoneyBear Biosciences, spoke on “Microarray Applications in Next-Generation Antibody-Drug Conjugate Development”
- 2. Assistant Professor Chih-Wei Lin (林志偉), China Medical University, lectured on “Antibody Screening Strategies in Cancer Immunotherapy”
- 3. Assistant Professor Chun-Chieh Yu (尤俊傑), Kaohsiung Chang Gung Hospital, presented “Decoding the Gut-Brain Axis Neuroinflammation Mechanism in Parkinson’s Disease”
- 4. Director Chiao-Hsiung Chuang (莊喬雄), Department of Physicians, NCKU Hospital, spoke on “Bacterial Antigen Analysis in Ulcerative Colitis Patients”
- 5. Professor Wei-Sheng Wu (吳謂勝), Department of Electrical Engineering, NCKU, introduced “Amino Acid Epitope Identification and Molecular Simulation Analysis in Kawasaki Disease”
In addition to professional lectures, the organizers arranged laboratory visits and free discussion sessions, allowing participants to witness microarray platform operations firsthand, gain deeper insights into research outcomes, and facilitate real-time interaction and collaboration among academics, clinicians, industry professionals, and university students. Notably, students from NCKU’s course “Industrialization and Expansion of Innovative Technology Services” applied their knowledge of industrialization and innovative service to the forum’s planning and execution, including event organization, agenda arrangement, and on-site management, gaining hands-on experience in translating cutting-edge research into commercial applications.
The High-Throughput Protein Microarray Technology and Biomedical Industry Service Alliance has long been dedicated to proteomics and antibody analysis, providing high-sensitivity immunoassays and customized analysis services to assist domestic and international research teams and companies in discovering disease biomarkers and promoting clinical translation. Through this Clinical Proteome Microarray Forum, the alliance aims to continue expanding its international collaboration network and enhance Taiwan’s visibility and influence in the fields of precision medicine and biomedical technology.
Group photo of the distinguished guests
Group photo of the participants
